Limits...
Meta-analysis comparing higher and lower dose radiotherapy for palliation in locally advanced lung cancer.

Ma JT, Zheng JH, Han CB, Guo QY - Cancer Sci. (2014)

Bottom Line: The combined odds ratios (ORs) indicated no significant difference in palliation of cough, chest pain, and hemoptysis between the higher dose and lower dose RT groups (combined ORs = 0.88, 1.83, 1.39, respectively).The 1- and 2-year OS rates were similar between the high and low dose RT groups (combined ORs = 1.09 and 1.38, respectively).This meta-analysis indicates that high dose (≥30 Gy) and lower dose (<30 Gy) RT provide similar symptom palliation and 1- and 2-year OS in patients with locally advanced lung cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.

Show MeSH

Related in: MedlinePlus

Forest plots of the meta-analysis comparing higher dose (≥30 Gy) versus lower dose (<30 Gy) radiotherapy for overall survival. (a) 1-year overall survival; (b) 2-year overall survival. CI, confidence interval; RT, radiotherapy.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317848&req=5

fig03: Forest plots of the meta-analysis comparing higher dose (≥30 Gy) versus lower dose (<30 Gy) radiotherapy for overall survival. (a) 1-year overall survival; (b) 2-year overall survival. CI, confidence interval; RT, radiotherapy.

Mentions: The Forest plot of the meta-analysis for the 1-year OS rate is presented in Figure 3(a). After pooling of the data, no significant heterogeneity among the studies was found (Q = 7.21, d.f. = 4, P = 0.125; I2 = 44.50%); therefore, a fixed-effects model was used for the meta-analysis of the 1-year OS rate. The combined OR revealed no significant difference in 1-year OS between patients treated with a higher RT dose compared to those with a lower RT dose. Among the five studies, ORs ranged from 0.50 to 1.66, with the combined OR = 1.09 (95% CI = 0.88–1.37, P = 0.425, Fig. 3a).


Meta-analysis comparing higher and lower dose radiotherapy for palliation in locally advanced lung cancer.

Ma JT, Zheng JH, Han CB, Guo QY - Cancer Sci. (2014)

Forest plots of the meta-analysis comparing higher dose (≥30 Gy) versus lower dose (<30 Gy) radiotherapy for overall survival. (a) 1-year overall survival; (b) 2-year overall survival. CI, confidence interval; RT, radiotherapy.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317848&req=5

fig03: Forest plots of the meta-analysis comparing higher dose (≥30 Gy) versus lower dose (<30 Gy) radiotherapy for overall survival. (a) 1-year overall survival; (b) 2-year overall survival. CI, confidence interval; RT, radiotherapy.
Mentions: The Forest plot of the meta-analysis for the 1-year OS rate is presented in Figure 3(a). After pooling of the data, no significant heterogeneity among the studies was found (Q = 7.21, d.f. = 4, P = 0.125; I2 = 44.50%); therefore, a fixed-effects model was used for the meta-analysis of the 1-year OS rate. The combined OR revealed no significant difference in 1-year OS between patients treated with a higher RT dose compared to those with a lower RT dose. Among the five studies, ORs ranged from 0.50 to 1.66, with the combined OR = 1.09 (95% CI = 0.88–1.37, P = 0.425, Fig. 3a).

Bottom Line: The combined odds ratios (ORs) indicated no significant difference in palliation of cough, chest pain, and hemoptysis between the higher dose and lower dose RT groups (combined ORs = 0.88, 1.83, 1.39, respectively).The 1- and 2-year OS rates were similar between the high and low dose RT groups (combined ORs = 1.09 and 1.38, respectively).This meta-analysis indicates that high dose (≥30 Gy) and lower dose (<30 Gy) RT provide similar symptom palliation and 1- and 2-year OS in patients with locally advanced lung cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.

Show MeSH
Related in: MedlinePlus